This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit

Tejara Capital fully exited its 520,503-share position in Arcutis Biotherapeutics (estimated $9.81 million based on quarterly average pricing), reducing the stake from 5.1% of the fund’s AUM to zero. Arcutis shares traded at $26.08 on Feb. 4 (up ~99.1% Y/Y) with a market cap of $3.19 billion; TTM revenue was $317.93 million and net income was a loss of $44.32 million. The company reported Q3 net product revenue of $99.2 million and reiterated guidance for FY2026 net product sales of roughly $455–$470 million, suggesting the sale was portfolio risk management rather than a bearish signal on fundamentals.

Analysis

Market structure: Tejara’s 520,503-share exit (~$9.8M, 5.1% of that fund’s AUM) is a portfolio rebalancing event, not a sector-wide de‑risking: ARQT’s ~$3.2B market cap and near‑term valuation are driven by ZORYVE prescription velocity and guidance (2026 sales $455–470M). Direct beneficiaries are stakeholders in specialty dermatology channels (specialty pharmacies, reps, payers with narrow formularies); losers would be any small-cap dermatology peers that lose access if payers consolidate. Options IV should compress after the Q4 rally, reducing volatility premium; wider risk‑on in biotech could tighten high‑yield spreads modestly but leave sovereign FX and commodities largely unaffected.

Risk assessment: Tail risks include an adverse safety/regulatory action or sudden payer formulary exclusion that could cause 30–50% downside in 1–3 months; a smaller but realistic execution miss (e.g., <80% of guided revenue) could trigger 15–25% repricing. Immediate (days) — modest selling pressure on headlines; short-term (1–3 months) — volatility around quarterly TRx and gross‑to‑net metrics; long-term (4–24 months) — company value will map to sustained operating leverage and durable gross margins. Hidden dependencies: gross‑to‑net rebates, specialty pharmacy capture rates, and rep productivity are key second‑order drivers that can swing margins by >500–1,000 bps.

Trade implications: Tactical: establish a small core long in ARQT with strict triggers — consider 1–2% portfolio position now, scale to 3% only if quarterly ARR/Net Product Revenue prints ≥$110–115M (next quarter) and Y/Y growth remains >30%. Hedged pair: long ARQT / short XBI (equal notional) to isolate execution upside vs broad biotech beta. Options: buy a 6–9 month call spread (e.g., $25–35) sized to 0.5–1% portfolio when IV <45%; if IV >45% prefer LEAP calls to avoid time decay. Rotate 2–3% from speculative early‑stage biotech into specialty pharma/derm names.

Contrarian angles: The market may be underweight sustained commercial execution risk rather than binary clinical risk — Tejara’s exit looks like risk control, not a negative signal, so a pullback of 10–15% could be a buying window. Conversely, valuation is not trivial: at $3.19B market cap and guidance midpoint $462.5M, ARQT trades near ~6.9x revenue — require operating margin improvements or consensus upside to justify higher multiples. Watch for quick negative inflection (stop-loss) if sequential TRx growth decelerates below +10% QoQ or management narrows guidance by >5% within the next 3 months.

Key Decisions for Investors

• Establish a 1–2% portfolio long in ARQT (buy up to $26, scale to 3% only if next-quarter Net Product Revenue ≥ $110–115M and Y/Y growth >30%; cut to zero if guidance is cut >5% or QoQ TRx growth < +10%).
• Enter a hedged pair: long ARQT (1% portfolio) vs short XBI (1% portfolio) to isolate company execution vs sector beta; reassess after next quarterly print (30–60 days).
• Implement a 6–9 month ARQT bull call spread (e.g., buy $25 / sell $35) sized to 0.5–1% portfolio if implied volatility ≤45%; if IV >45% use 12–18 month LEAP calls instead to reduce theta risk.
• Rotate 2–3% from early‑stage biotech holdings into specialty dermatology/specialty pharma names (including ARQT) over the next 30 days, prioritizing companies with clear payer coverage and positive gross‑to‑net trends.
• Monitor weekly ZORYVE TRx data, gross‑to‑net (% of net sales), and specialty pharmacy capture rates; treat any single-week TRx deceleration >15% or gross‑to‑net increase >500 bps as a trigger to reduce ARQT exposure by half within 5 trading days.